Foley Hoag Advises Zosano Pharma on Exclusive Licensing Agreement with Eli Lilly
January 6, 2015
Foley Hoag LLP advised Zosano Pharma Corporation (Zosano), a private biopharmaceutical company and a pioneer in the field of transdermal drug delivery, in its exclusive licensing agreement with Eli Lilly and Company to develop ZP-PTH -- Zosano’s proprietary formulation of parathyroid hormone 1-34 (PTH) -- using Zosano’s microneedle patch system for the treatment of osteoporosis patients.
Under the terms of the agreement, Zosano has granted Lilly an exclusive worldwide license to commercialize ZP-PTH. Lilly will make an equity investment of up to $15 million in Zosano concurrent with the consummation of Zosano’s initial public offering of equity securities, and will make payments of up to a total of $300 million upon achievement of certain regulatory and sales milestones. Zosano is also eligible to receive double-digit royalties on sales of products in major markets and will receive reimbursement of manufacturing costs.
Zosano is a clinical stage specialty pharmaceutical company that has developed a proprietary transdermal microneedle patch system to deliver its proprietary formulations of existing drugs through the skin for the treatment of a variety of indications.
About Foley Hoag LLP
Foley Hoag provides innovative, strategic legal services to public, private and government clients across the globe. We have premier capabilities in the life sciences, healthcare, technology, energy, professional services and private funds fields, and in cross-border disputes. The diverse backgrounds, perspectives and experiences of our lawyers and staff contribute to the exceptional senior level service we deliver to clients ranging from startups to multinational companies to sovereign states. For more information, visit www.foleyhoag.com or follow @FoleyHoag on Twitter.